AM-2201

AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor. It is part of the AM series of cannabinoids discovered by Alexandros Makriyannis at Northeastern University.

Hazards

Convulsions have been reported including at doses as low as 10 mg.

Recreational use of AM-2201 in the United States has led to it being specifically listed in a proposed 2011 amendment to the Controlled Substances Act, aiming to add a number of synthetic drugs into Schedule I. As of November 2011, there have been no reports of death associated with the drug. The acute toxicity and long term side effects associated with the use of AM-2201 are unknown.

Pharmacology

AM-2201 is a full agonist for cannabinoid receptors. Affinities are: with a K_i of 1.0 nM at CB₁ and 2.6 nM at CB₂. The 4-methyl functional analog MAM-2201 probably has similar affinities. AM-2201 has an EC₅₀ of 38 nM for human CB₁ receptors, and 58 nM for human CB₂ receptors. AM-2201 produces bradycardia and hypothermia in rats at doses of 0.3-3 mg/kg, comparable to the potency of JWH-018 in rats, suggesting potent cannabinoid-like activity.